8 February 2024
Calidi Biotherapeutics is developing the next generation of targeted immunotherapies using the combination of stem cells with oncolytic viruses. In this video, Dr. Antonio F. Santidrian, PharmD, Ph.D., Chief Scientific Officer at Calidi Biotherapeutics, describes how this unique tumor-agnostic technology protects the virus against the immune system, allowing the therapy to have an immediate and powerful effect on the target tumor. Learn about products in development for high-grade glioma, advanced solid tumors and metastatic solid tumors, and Santidrian’s thoughts on the future of immunotherapy.
This video interview is part of the SelectScience® Biopharmaceuticals feature. Visit the feature to discover more news about the latest advances in biopharma and the technologies supporting development.